TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT02235857: Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Sponsor: Kaneka Medical America LLC · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 35 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,626,800

Rescue Site Savings

+$1,062,400

Unlock Full NCT02235857 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02235857 Rescue Dossier →